Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of Siltuximab in Multicentric Castleman's Disease
NCT01400503Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2011
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 2 trial of siltuximab in multicentric Castleman disease (MCD), sponsored by Janssen Pharmaceutical. Started Apr 2011; status: completed.
02
Drugs
siltuximab
03
Conditions
multicentric Castleman disease (MCD)
Beyond the preview
Go deeper on NCT01400503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01400503.